First in-human study of golodirsen for Duchenne muscular dystrophy shows safety and biologic activity

Duchenne muscular dystrophy
Histopathology of gastrocnemius muscle from patient who died of pseudohypertrophic muscular dystrophy, Duchenne type. Cross section of muscle shows extensive replacement of muscle fibers by adipose cells. Credit: Wikimedia Commons/Public Domain

This first-in-human study of golodirsen showed its long-term safety and biologic activity in patients with Duchenne Muscular Dystrophy (DMD). The approved exon-skipping therapy is designed to enable the production of functional dystrophin proteins, as described in the peer-reviewed journal Nucleic Acid Therapeutics.

Golodirsen was tested in ambulatory patients with exon 53 skip amenable DMD. They were at an age associated with progressive deterioration and declining ambulatory function.

Francesco Muntoni, MD, from University College London, and coauthors, on behalf of the SKIP-NMD Study Group, conducted a two-part Phase 1/2 trial of long-term golodirsen treatment. Part 1 included a safety review. Part 2 was a 168-week evaluation of golodirsen 30 mg/kg. The primary endpoints were dystrophin protein expression and a 6-minute walk test. Golodirsen significantly increased dystrophin protein expression 16-fold and exon skipping 28.9-fold. After 3 years, the 6-minute walk test declined by only 99.0 meters for golodirsen-treated patients versus a decline of 181.4 meters for the control group, and loss of ambulation occurred in 2 of 25 golodirsen-treated versus 5 of 19 control patients.

"The results presented herein provide evidence for the biologic activity and long-term safety of golodirsen in a declining DMD population, supporting evaluation of golodirsen in an ongoing Phase 3 trial," concluded the investigators.

"These long-term clinical outcome data support the contention that systemically administered morpholino oligomers can significantly improve the expected disease course in patients with Duchenne Muscular Dystrophy." says executive editor Graham C. Parker, Ph.D., the Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.

More information: Laurent Servais et al, Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial, Nucleic Acid Therapeutics (2021). DOI: 10.1089/nat.2021.0043
Citation: First in-human study of golodirsen for Duchenne muscular dystrophy shows safety and biologic activity (2021, November 30) retrieved 3 December 2022 from https://medicalxpress.com/news/2021-11-in-human-golodirsen-duchenne-muscular-dystrophy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

New treatment for muscular dystrophy wins US regulatory approval

 shares

Feedback to editors